Skip to main content
Search
Main content
Sarah Mizielinska profile

Dr Sarah Mizielinska

Group Leader

Understanding the precise mechanisms of nucleocytoplasmic dysfunction in FTD and ALS

Biography

Dr Sarah Mizielinska joined the UK DRI at King's to establish her first group in 2018. Also a Lecturer in Dementia & Neurodegenerative Disorders at the Maurice Wohl Clinical Neuroscience Institute, King’s College London, her research focuses on molecular and cellular mechanisms of neurodegeneration in dementia and motor neuron diseases, especially those caused by repeat expansions. Obtaining her PhD from the University of Dundee, Sarah went on to complete postdoctoral training at UCL, and was awarded the UCL Early Careers Neuroscience Prize in 2014. Sarah's lab at the UK DRI at King's investigates transport disruption between neuronal nuclear and cytoplasmic sub-compartments in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Mizielinska Lab

Explore the Mizielinska Lab, aiming to gain a greater understanding of the precise mechanisms of nucleocytoplasmic dysfunction in FTD and ALS at the molecular level to inform disease pathogenesis and potential accurate therapeutic interventions

iPSC cells